Status:

COMPLETED

A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection

Lead Sponsor:

Eastern Hepatobiliary Surgery Hospital

Conditions:

Hepatocellular Carcinoma

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

The aim of this study is to analyze the therapeutic effect of adjuvant Licartin therapy after resection.Patients receiving curative resection (R0) were randomized to postoperative Licartin group and n...

Detailed Description

Hepatocellular carcinoma (HCC) represents a major health care challenge in the present era, with its incidence rate of 71128 cases and the mortality rate of 679871 cases during 2007 in the world. Alth...

Eligibility Criteria

Inclusion

  • Patients with HCC who received curative liver resection (R0)and with positive expression of HAb18G/CD147 in the HCC tissues
  • Karnofsky Performance Score performance over 60
  • The functions of the kidney, heart and lung and the blood system are normal and fittable for Licardin therapy.
  • The liver function is of grade A or B in Child-Pugh classification.
  • Patients give consent to the test.

Exclusion

  • Negative expression of HAb18G/CD147 in the HCC tissues
  • Allergic history to biologic products(Licartin)
  • Any of the situation list below: WBC less than 2000/ml, Hb less than 90g/L or PLT less than 50000/ml, bilirubin level more than 2.5 times the upper limit of normal value, serum albumin less than 32 g/l.
  • Severed disease of the heart, lung, kidney, brain and blood system.
  • Other severed disease might affect the trial .
  • Patients would not sign the consent to the trial.

Key Trial Info

Start Date :

December 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2010

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT00819650

Start Date

December 1 2008

End Date

December 1 2010

Last Update

April 1 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Eastern hepatobilliary surgery hospital

Shanghai, Shanghai Municipality, China, 200438

A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection | DecenTrialz